Nature Search

Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen

Charles Flexner
Brian R. Murphy
Bernard Moss
Research15 Sept 1988
Nature

Volume: 335, P: 259-262
Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds

CHARLES HEIDELBERGER
N. K. CHAUDHURI
J. SCHEINER
Research30 Mar 1957
Nature

Volume: 179, P: 663-666
Prevention of vaccinia virus infection in imiminodeficient mice by vector-directed IL-2 expression

Charles Flexner
Ambros Hügin
Bernard Moss
Research19 Nov 1987
Nature

Volume: 330, P: 259-262
Retinoblastoma in transgenic mice

Jolene J. Windle
Daniel M. Albert
Pamela L. Mellon
Research15 Feb 1990
Nature

Volume: 343, P: 665-669
Petrological and tectonic segmentation of the East Pacific Rise, 5°30′–14°30′ N

Charles H. Langmuir
John F. Bender
Rodey Batiza
Research31 Jul 1986
Nature

Volume: 322, P: 422-429
Latent infection of CD4⁺ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

Diana Finzi
Joel Blankson
Robert F. Siliciano
Research01 May 1999
Nature Medicine

Volume: 5, P: 512-517
Tipranavir

Tipranavir (Aptivus; Boehringer Ingelheim) was given accelerated approval by the FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents in June 2005. It is the first in a new class of non-peptidic HIV-1 protease inhibitors, and is active against HIV-1 strains that are resistant to other protease inhibitors.

Charles Flexner
Guy Bate
Peter Kirkpatrick
Comments & Opinion01 Dec 2005
Nature Reviews Drug Discovery

Volume: 4, P: 955-956
HIV drug development: the next 25 years

HIV has been the most active field of antiviral drug research and development since the discovery of the virus a quarter of a century ago. Flexner provides an overview of current opportunities and novel targets in HIV drug discovery, and analyses the central questions pertinent for the next 25 years of drug development for HIV.

Charles Flexner
Reviews01 Dec 2007
Nature Reviews Drug Discovery

Volume: 6, P: 959-966
Growth and Development of Academic Pediatrics in North America: Presidential Address to the American Pediatric Society, April 28, 1971

Charles A Janeway
Research01 Oct 1971
Pediatric Research

Volume: 5, P: 560-565
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa

Long-acting injectable drugs for viral suppression of HIV are not yet available in African settings. Here, the authors present a mathematical modelling and cost effectiveness study of a long-acting drug combination in adults living with HIV in East, Central, Southern and West Africa.

Andrew Phillips
Jennifer Smith
Paul Revill
ResearchOpen Access01 Jul 2025
Nature Communications

Volume: 16, P: 1-13
Non-hydrophobic extracytoplasmic determinant of stop transfer in the prion protein

C. Spencer Yost
Charles D. Lopez
Vishwanath R. Lingappa
Research15 Feb 1990
Nature

Volume: 343, P: 669-672
Christian Faith in the World of Science

CHARLES E. RAVEN
Books & Arts03 Sept 1955
Nature

Volume: 176, P: 410-411
Computer science: Digital dawn

Thomas Misa ponders a history of computing that focuses firmly on John von Neumann and the 'Princeton crowd'.

Thomas Misa
Books & Arts29 Feb 2012
Nature

Volume: 483, P: 32-33
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies

Non-adherence to daily drug regimens is responsible for many negative clinical effects including drug resistance in life-long treatments for HIV. Here, the authors report on a HIV prodrug nanoparticle platform for long-acting sustained release of water-soluble drug compounds following injection.

James J. Hobson
Amer Al-khouja
Steve P. Rannard
ResearchOpen Access29 Mar 2019
Nature Communications

Volume: 10, P: 1-10
American Pediatric Society Presidential Address 1995: Disease, War, and Biology: Languages for Medicine—and Pediatrics

Charles R Scriver
Research01 Dec 1995
Pediatric Research

Volume: 38, P: 819-829
Targeting bladder function with network-specific epidural stimulation after chronic spinal cord injury

April N. Herrity
Sevda C. Aslan
Susan J. Harkema
ResearchOpen Access01 Jul 2022
Scientific Reports

Volume: 12, P: 1-15

Search

Filter By:

Search

Quick links